Luigi MD - Genenta Science CoFounder Board
| GNTA Stock | USD 4.79 0.10 2.13% |
Insider
Luigi MD is CoFounder Board of Genenta Science SpA
| Age | 65 |
| Address | Via Olgettina No. 58, Milan, MI, Italy, 20132 |
| Phone | 39 02 26 43 46 81 |
| Web | https://www.genenta.com |
Genenta Science Management Efficiency
The company has return on total asset (ROA) of (0.2583) % which means that it has lost $0.2583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4289) %, meaning that it created substantial loss on money invested by shareholders. Genenta Science's management efficiency ratios could be used to measure how well Genenta Science manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.55. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Genenta Science's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.3 M, whereas Net Tangible Assets are forecasted to decline to about 13.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Eliem Therapeutics | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Carl Langren | Lumos Pharma | 69 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Jeff York | Seres Therapeutics | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| MD BA | Lumos Pharma | 69 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.26 |
Genenta Science SpA Leadership Team
Elected by the shareholders, the Genenta Science's board of directors comprises two types of representatives: Genenta Science inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genenta. The board's role is to monitor Genenta Science's management team and ensure that shareholders' interests are well served. Genenta Science's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genenta Science's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefania Mazzoleni, Director Development | ||
| Pierluigi Paracchi, Chairman CoFounder | ||
| Carlo MD, Chief Development | ||
| Richard Slansky, Chief Officer | ||
| Tim Obara, Head Devel | ||
| Barbara Regonini, Director Finance | ||
| Luigi MD, CoFounder Board | ||
| Bernard MD, CoFounder Board |
Genenta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genenta Science a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 69.89 M | ||||
| Shares Outstanding | 18.29 M | ||||
| Shares Owned By Insiders | 38.68 % | ||||
| Shares Owned By Institutions | 7.77 % | ||||
| Number Of Shares Shorted | 5.26 K | ||||
| Price To Book | 4.97 X | ||||
| EBITDA | (11.69 M) | ||||
| Net Income | (11.65 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genenta Science SpA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genenta Science's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genenta Science Spa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genenta Science Spa Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genenta Science SpA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genenta Science. If investors know Genenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genenta Science listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.26) | Return On Equity (0.43) |
The market value of Genenta Science SpA is measured differently than its book value, which is the value of Genenta that is recorded on the company's balance sheet. Investors also form their own opinion of Genenta Science's value that differs from its market value or its book value, called intrinsic value, which is Genenta Science's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genenta Science's market value can be influenced by many factors that don't directly affect Genenta Science's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genenta Science's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genenta Science is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genenta Science's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.